M
Marcela V. Maus
Researcher at Harvard University
Publications - 224
Citations - 20307
Marcela V. Maus is an academic researcher from Harvard University. The author has contributed to research in topics: Chimeric antigen receptor & T cell. The author has an hindex of 57, co-authored 175 publications receiving 14073 citations. Previous affiliations of Marcela V. Maus include University of Pennsylvania & Ragon Institute of MGH, MIT and Harvard.
Papers
More filters
Journal ArticleDOI
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee,Bianca Santomasso,Frederick L. Locke,Armin Ghobadi,Cameron J. Turtle,Jennifer N. Brudno,Marcela V. Maus,Jae H. Park,Elena Mead,Steven Z. Pavletic,William Y. Go,Lamis K. Eldjerou,Rebecca Gardner,Noelle V. Frey,Kevin J. Curran,Karl S. Peggs,Marcelo C. Pasquini,John F. DiPersio,Marcel R.M. van den Brink,Krishna V. Komanduri,Stephan A. Grupp,Sattva S. Neelapu +21 more
TL;DR: The goal is to provide a uniform consensus grading system for CRS and neurotoxicity associated with immune effector cell therapies, for use across clinical trials and in the postapproval clinical setting.
Journal ArticleDOI
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.
Donald M. O'Rourke,MacLean Nasrallah,Arati Desai,J. Joseph Melenhorst,Keith Mansfield,Jennifer J.D. Morrissette,Maria Martinez-Lage,Steven Brem,Eileen Maloney,Angela Shen,Randi Isaacs,Suyash Mohan,Gabriela Plesa,Simon F. Lacey,Jean-Marc Navenot,Zhaohui Zheng,Bruce L. Levine,Hideho Okada,Carl H. June,Jennifer Brogdon,Marcela V. Maus +20 more
TL;DR: The initial experience with CAR T cells in recurrent GBM suggests that although intravenous infusion results in on-target activity in the brain, overcoming the adaptive changes in the local tumor microenvironment and addressing the antigen heterogeneity may improve the efficacy of EGFRvIII-directed strategies in GBM.
Journal ArticleDOI
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje,Jesus G. Berdeja,Yi Lin,David S. Siegel,Sundar Jagannath,Deepu Madduri,Michaela Liedtke,Jacalyn Rosenblatt,Marcela V. Maus,Ashley Turka,Lyh Ping Lam,Richard A. Morgan,Kevin G. Friedman,Monica Massaro,Julie Wang,Greg Russotti,Zhihong Yang,Timothy B. Campbell,Kristen Hege,Fabio Petrocca,M. Travis Quigley,Nikhil C. Munshi,James N. Kochenderfer +22 more
TL;DR: The initial toxicity profile of a BCMA‐directed cellular immunotherapy for patients with relapsed or refractory multiple myeloma is reported andCAR T‐cell expansion was associated with responses, and CAR T cells persisted up to 1 year after the infusion.
Journal ArticleDOI
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
Gerald P. Linette,Edward A. Stadtmauer,Marcela V. Maus,Aaron P. Rapoport,Bruce L. Levine,Lyndsey Emery,Leslie A. Litzky,Adam Bagg,Beatriz M. Carreno,Patrick J. Cimino,Gwendolyn Binder-Scholl,Dominic P. Smethurst,Andrew B. Gerry,Nick Pumphrey,Alan D. Bennett,Joanna E. Brewer,Joseph Dukes,Jane Harper,Helen K. Tayton-Martin,Bent K. Jakobsen,Namir J. Hassan,Michael Kalos,Carl H. June +22 more
TL;DR: Clinical testing of engineered T cells expressing an affinity-enhanced TCR against HLA-A*01-restricted MAGE-A3 demonstrated that TCR-engineered T cells can have serious and not readily predictable off-target and organ-specific toxicities and highlight the need for improved methods to define the specificity of engineeredTCRs.
Journal ArticleDOI
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
Gregory L. Beatty,Andrew R. Haas,Marcela V. Maus,Drew A. Torigian,Michael C. Soulen,Gabriela Plesa,Anne Chew,Yangbing Zhao,Bruce L. Levine,Steven M. Albelda,Michael Kalos,Carl H. June +11 more
TL;DR: Findings support the development of mRNA CAR-based strategies for carcinoma and other solid tumors by showing the potential of using mRNA-engineered T cells to evaluate, in a controlled manner, potential off-tumor on-target toxicities and showing that short-lived CAR T cells can induce epitope spreading and mediate antitumor activity in patients with advanced cancer.